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Cancer is known to be an extremely complex disease that is caused by a variety of different 
agents, including radiation. An understanding of the molecular mechanisms that generate 
cancer, and the link between molecular features and aetiology, prognosis and response 
to treatment is pivotal in the successful treatment of the patient. The unprecedented 
increase in thyroid cancer following the accident at the Chernobyl power plant provided 
the opportunity to understand the molecular biology of this type of malignancy, and 
to link molecular features with radiation aetiology. Thyroid cancer in young people is a 
rare disease, with an incidence rate of around 0.5–1.5 cases per million per year [1]. Initial 
reports suggested that thyroid cancers that were observed in young people following the 
Chernobyl accident were different from those from an unexposed population. However, 
more careful analysis showed that this rare variant, a solid type of papillary cancer that 
showed extensive invasion, was common in young patients, whether exposed to radiation 
or not [2]. This contrasts with the classic and follicular variants of papillary carcinoma found 
more commonly in adults. Since the pathological appearance of a tumor is related to the 
integration of the molecular events that are involved in its generation, a number of studies 
have concentrated on defining the various genetic and epigenetic changes involved.
Cases from Ukraine, provided via the Chernobyl Tissue Bank (CTB) have been used 
extensively in these analyses. The early studies concentrated on the frequency of activation 
of oncogenes already known to be pathogenic in papillary thyroid carcinoma (PTC). 
However, more complex molecular techniques have developed in the last decade, and 
the later studies concentrate on the identification of multiple molecular changes in these 
tumors.
Changes in the Genome
Somatic DNA – single oncogene studies
Genetic alterations that induce the Mitogen activated protein kinase (MAPK) signalling 
pathway are common in sporadic PTC. The MAPK pathway is involved in regulation of 
differentiation, survival and cell growth, and its malfunction is well known to be tumor 
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promoting [3]. Common alterations include both gene rearrangements and point mutations. 
Inversions and translocations of a given chromosomal region can lead to an activation of 
an oncogene that is inactive in the normal thyroid cell. The commonest rearrangements in 
PTC are those that involve paracentric inversion of part of chromosome 10, RET/PTC1 and 
RET/PTC3, resulting in fusion with the H4 gene (CCDC6, D10S170) and NCOA4 gene (RFG, 
ELE1), respectively. The BRAF oncogene which is frequently mutated (point mutation) in 
adult PTC has also been found to be activated in a small number of radiation-induced PTC 
following inversion on chromosome 7q [4]. Alterations in the BRAF and RET oncogenes are 
usually mutually exclusive [5,6].
Other studies have identified chromosomal breakpoints on 1p32-36, 1p11-13, 1q22, 
3p25-26 and 7q32-36 [7-9] and a deletion on 11q [10], but their importance in radiation-
induced childhood PTC remains unclear. One reason why some rearrangements occur more 
frequently than others may be the close proximity of the two gene loci participating in the 
rearrangement within the nucleus. This theory is supported in a study by Nikiforova et al. 
on the PTC specific translocation of the RET and H4 genes thereby forming RET/PTC1 [11]. In 
vitro irradiation studies show increased DNA end-joining enzymatic activity which argues in 
favour of a radiation-specific response related to gene rearrangement in thyroid cells [12].
RET/PTC gene rearrangement in Ukrainian cases
The RET gene is located on chromosome 10q11.2. Its breakpoints for rearrangement 
are all located within intron 11. The encoded receptor tyrosine kinase has an extracellular 
domain, a transmembrane domain and an intracellular domain [13]. Fusion of RET with 
other genes provides the tyrosine kinase domain with a new promoter and 5’ coding 
region which leads to constitutive expression of the protein and transmembrane domain 
is substituted by dimerization domains for ligand-independent activation [14]. There are 
17 different RET/PTC rearrangements that have been identified in PTC, but inversions 
of chromosome 10 resulting in RET/PTC1 and RET/PTC3 are the most frequent. The RET 
proto-oncogene was already known to be involved in papillary thyroid carcinogenesis 
in studies of sporadic cases where rearrangements have been found in up to 40% of 
cases. Rearrangement has been shown to be restricted to the papillary type of thyroid 
cancer [15,16] and occur frequently in small papillary carcinomas suggesting that it is 
likely to be a driving event in early tumorigenesis. The breakpoint in the DNA occurs 
within an intron, which permits the use of reverse transcriptase PCR (RT-PCR) using 
RNA extracted from the tumors as a useful tool for identifying PTCs that harbour RET/
PTC rearrangements. However, studies using this technique need to be interpreted with 
caution, as it has been shown that the results are heavily influenced by the PCR protocol 
used and tumor heterogeneity [17].
Initial studies post Chernobyl were carried out on Belarussian cohorts [18-20] and 
suggested an increased frequency of RET/PTC rearrangement in radiation induced PTCs in 
children. In a study on Ukrainian cases, reported by Santoro et al. [21], of the 106 papillary 
carcinomas which produced amplifiable RNA and were analysed for RET rearrangement using 
rearrangement specific RT-PCR, 20 were identified as positive for RET/PTC1 and 15 for RET/
PTC3; one other tumor was positive for both RET/PTC1 and RET/PTC3. Analysis of the expression 
145
Molecular biology studies of Ukrainian thyroid cancer after Chernobyl
of the extracellular and tyrosine kinase domains was also performed independently in a 
different institute in 45 of the 106 cases. Twenty-two of these 45 tumors were positive for 
expression of RET tyrosine kinase. No tumor sample showed positivity for the expression of 
the RET extracellular domain only, suggesting that the RET tyrosine kinase expression was due 
to the presence in these tumors of a RET rearrangement fusing the tyrosine kinase domain 
of the RET gene with an active promoter. Among these 45 cases investigated for RET tyrosine 
kinase expression, there were 20 with an identified PTC1 or -3 rearrangement, including 
one tumor which showed both PTC1 and -3; 18 showed RET tyrosine kinase expression. The 
unexpected negative RET tyrosine kinase in two cases may have been the result of a lack of 
sensitivity. Twenty-five cases lacked either a PTC1 or -3 rearrangement, 21 were negative for 
RET tyrosine kinase expression, while four were positive. The positive RET tyrosine kinase in 
these four cases could have resulted from the presence of a RET rearrangement other than 
PTC1 or -3. Overall agreement between the two techniques was therefore present in 39 out 
of 45 cases (87%). The type of RET rearrangement correlated with tumor morphology; RET/
PTC3 dominated in the predominantly solid subtype and RET/PTC1 was more common in 
the classical subtype of PTC. This is consistent with previous studies on other Chernobyl-
related tumor cohorts [20,22,19] and with transgenic models of thyroid cancer in animals 
[23,24].  A cohort of 28 PTCs from Ukraine and 39 from Belarus was examined by Thomas et 
al. [25]. Patients received surgery 9-11 years after exposure to radiation and their age range at 
operation was between 6-18 years. 60.7% of the Ukrainian and 51.3% of the Belarussian cohort 
were RET/PTC positive. 23 PTCs harboured the RET/PTC3 rearrangement and 14 patients the 
RET/PTC1. RET/PTC3 was found to be associated with the dominantly solid subtype of PTC, 
whereas RET/PTC1 was associated with the classic subtype of PTC. Matched normal thyroid 
tissue samples were negative for RET rearrangements. In addition, lymph node metastases 
of 8 Ukrainian patients were examined. RET rearrangement was detected in all cases where 
the rearrangement was already present in the primary tumor. One metastasis was found to 
be RET/PTC positive although the primary tumor was negative. It had been shown that both 
ionizing and external radiation [26] were able to induce RET rearrangements in vitro [27], 
suggesting that RET/PTC rearrangement in these tumors was a potential marker for radiation 
exposure. RET/PTC3 rearrangement is more prevalent than RET/PTC1 and linked to the solid 
subtype, which was, at the time believed to be more frequent in radiation induced tumors. In 
the rare cases where it occurs in adult onset sporadic PTC, it was linked to a more aggressive, 
invasive phenotype with a higher potential to metastasize [28]. Since the early pathological 
studies suggested that the PTCs found in children post Chernobyl were more aggressive than 
their adult counterparts, it seemed logical to suggest that this rearrangement was important 
in the solid subtype, aggressive PTCs, that were frequent in the short latency PTCs, which 
were being examined at that time.
However, in all the studies reported above there was an inherent problem.  Frequencies 
of RET rearrangement in young onset, post Chernobyl PTCs were compared with the 
frequencies of this oncogene in adult PTCs. Later studies [29], some using age-matched 
controls [30], have shown that the frequency of RET rearrangement in early onset PTC, 
regardless of prior radiation exposure of the patient,  is much higher than that found in 
adult PTC, suggesting that the initial conclusions on RET rearrangement being a biomarker 




RT-PCR is a useful tool, but does not allow identification of the proportion of cells that 
carry the RET/PTC rearrangement. It was noted that the strength of RT-PCR signal for RET/
PTC varied considerably between cases, and that this might suggest that this may represent 
intratumoral heterogeneity. Unger et al. [31] therefore examined 32 patients from the 
Ukrainian cohort with a tumor latency of 9-12 years for the intratumoral distribution of 
the RET/PTC rearrangement using FISH. FISH is a DNA hybridization method targeting 
metaphase chromosomes or interphase nuclei on tissue sections. FISH is capable of 
detecting RET rearrangements without further knowledge of the fusion partners. It allows 
for examination at the single cell level and can contribute to a better understanding of the 
tumor heterogeneity. Interphase FISH was chosen for the detection of the chromosomal 
alterations involving the RET gene, [31,32]. Two YAC probes including regions within the 
RET target locus and distal to the RET sequence were chosen and labelling was performed 
using two different fluorescent dyes (Fig. 7.1). A confocal laser scanning microscope was 
used for visualisation. Cell nuclei were scored for the presence of a separated red and 
green FISH signal in addition to an overlapping signal. This helps to avoid misclassification, 
which is dependent on the location of the interphase chromosome 10 within the nucleus 
and the spatial proximity of RET to putative rearrangement partners. Overlapping signals 
occur only in normal nuclei, and split signals indicate an aberration of the RET gene. This 
approach has been further validated by using careful selection of controls, including RET/
PTC positive and negative cell lines as well as wild type RET expressing controls (Fig. 7.2).
Figure 7.1. Mapping of YAC probes 313F4, 210H10 and 344H4 on chromosome 10q11.2. YAC 
clones 313F4 and 214H10 (FITC-labelled, green) map proximal to and include the RET locus, 344H4 
(Cy3-labelled, red) maps distal to RET. Exons and different parts of the RET gene are indicated below 
(EC=extracellular domain, Cys=cystein-rich domain, TM=transmembrane domain, TK=tyrosine 
kinase domain).
The study reported by Unger et al. [31], comprised 29 PTCs, two follicular adenomas, 
and a follicular cancer. Detection of the RET rearrangement with conventional qRT-PCR 
revealed that 13 (40.6%) of the patients expressed the TK domain of RET, and in only 
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two and three patients, respectively, was a clear RET/PTC1 and RET/PTC3 signal detected. 
Investigation of the cases with FISH was more sensitive and 23 patients (72%) were positive 
for the RET rearrangement. A threshold for positivity was set as evidence of rearrangement 
in a minimum of 7% of cells within a tumor. The highest observed frequency of cells 
bearing the RET rearrangement positive FISH signal was 46%. In none of the tumors was 
a FISH positive signal observed in 100% of tumor cells. Further analysis showed that the 
distribution of FISH positive cells was inhomogeneous. 
Figure 7.2. Example of FISH analysis with RET-specific YAC probes using confocal laser scanning 
microscopy (CLSM). Three different areas were randomly selected from the tumor as indicated at the 
40x magnification image (TOPRO image only, top center). One viewing area (left side) shows only 
normal cells exhibiting overlapping FISH signals. Two other viewing areas (middle and right side) 
show a cluster of aberrant cells identified by split FISH signals (arrows). All images are superimposed 
from approximately ten different slices throughout the thickness of the tissue section. For a more 
precise evaluation a stepwise scoring every 0.5 µm is applied. 
The same group repeated the RET rearrangement analysis on a Ukrainian cohort 
of 13 patients presenting with PTC after a shorter latency of 4-8 years post Chernobyl 
[32]. They compared this short latency group to the long latency group described 
previously for the distribution of the RET rearrangement within a given tumor sample. 
Examination with interphase FISH showed 10 of the patients (77%) were positive for a RET 
rearrangement with a frequency of rearranged cells between 11-54%. In 9 cases, the RET 
rearrangement was homogenously distributed all over the tumor tissue, whereas one case 
showed distinct clustering in certain areas of the tumor. Both studies identified a similar 
frequency of intertumoral rearrangement of RET, but the intratumoral distribution of the 
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RET rearrangement between the groups differed significantly. The longer latency group 
included a higher frequency of tumors with a heterogenous distribution and clustering 
of the rearrangement. At the same time, others had noted that tumor morphology was 
changing from a predominantly solid subtype in the shorter latency to a solid-follicular 
subtype in the longer latency group [33]. The reason for this may be the outgrowth of 
distinct subclones in longer latency tumors or the presentation of RET/PTC as a second 
event in thyroid carcinogenesis.
In a later study, reported by Hieber et al. [34], interphase FISH analysis was used 
to assess RET rearrangements of the cases. Aside from five other chromosomal 
rearrangements, 16 of the cases (72%) were positive for RET rearrangements. This is a 
rate similar to that observed in other studies [31,32]. With a threshold for RET positive of 
7.1%, the number of rearranged cells per case varied from 10.6% to 41.5%. There was no 
obvious correlation with age or gender of the patients, but the median age at operation 
of the patients carrying rearrangements was higher (22 years) compared to the group 
with no rearrangement (18 years). Within the group carrying rearrangements, older 
patients showed greater tumor heterogeneity with respect to RET/PTC rearrangements, 
consistent with the earlier study by Unger et al. [31].
The BRAF proto-oncogene
BRAF is a RAF kinase which plays an important role in the MAPK pathway. It is 
member of the family of RAF proteins, and due to its serine/threonine kinase activity 
it phosphorylates the MAPK/ERK kinase upon stimulation by RAS [35]. It is frequently 
mutated in thyroid cancer, where the point mutation at nucleotide position 1799 is 
the most prominent one. A transversion from thymine to adenine (T1799A) changes 
the amino acid sequence in codon 600 from valine to glutamic acid (V600E); thus the 
abbreviations used to designate this mutation are BRAFT1799A or BRAFV600E. This results in 
constituent activation of the gene, thus activating the MAPK pathway. The frequency of 
mutation varies in a number of studies from 36-69% in adult papillary thyroid carcinoma 
[36,37], including one study on Ukrainian tumors [30]. In adult cases, BRAF mutation 
significantly correlates with clinical parameters in PTC such as distant metastases, 
advanced clinical stage and disease specific mortality [38]. In children, the involvement 
of BRAF has been found to be somewhat different.  Kumagai et al. [39] performed a study 
on childhood PTC from Japan and Ukrainian patients with PTC following the Chernobyl 
accident, and compared the frequency of BRAF mutation with that found in adult PTCs. 
Sequence analysis of the BRAFT1799A mutation in exon 15 found only one positive case in 
the young Japanese cohort. No mutations in K-, H- or N-RAS were detected. The same 
result was obtained for the childhood group (aged under 15 at diagnosis) within the 
Ukrainian cohort. However, among the cases of young adults, 8 out of 33 carried the 
BRAFT1799A mutation and two other cases carried RAS mutations, one in NRAS codon 61 and 
one in HRAS codon 61. The Ukrainian group was also examined for RET rearrangements. 
5 out of 15 in the childhood group exhibited the rearrangement, and 12 out of 33 in the 
group of young adults. Mutation of BRAF and rearrangement of the RET oncogene were 
mutually exclusive. Interestingly, in this study, the presence of the mutation was not 
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associated with large tumor size, regional lymph node invasion, extrathyroidal invasion, 
or distant metastases. 
Lima et al. [40] examined a cohort of 34 post-Chernobyl paediatric PTC from Ukraine 
and found that four were positive for the BRAFV600E mutation. 14 of the patients had a RET/
PTC rearrangement, but BRAF mutation and RET rearrangement were, again, mutually 
exclusive. The BRAF mutation occurs predominantly in the papillary and follicular 
variants, whereas the RET rearrangements were more common in the solid subtype of 
the tumor. The control group of sporadic pediatric PTCs contained no solid variants, and 
the frequency of RET rearrangement was not determined. Powell et al. [30] used 67 cases 
of post-Chernobyl PTC from Ukraine to examine whether the BRAF mutation was related 
to the age of the patients or the radiation exposure. 32 patients were aged above 30 at 
time of clinical presentation, and 35 patients were under 16. All patients, exposed or 
unexposed to radiation, were residents in the Ukraine and hence an ethnic difference as 
confounder can be excluded. Paired tumor – normal samples were analysed and 18 out 
of the 32 adult cases were found to harbour the BRAFV600E mutation in the tumor but not 
in the normal tissue. The tumor morphology was of dominantly classic or dominantly 
follicular subtype. Only one child in the group of 35 exposed cases was positive for the 
mutation and none of the sporadic PTCs. Interestingly, the one case bearing the BRAF 
mutation was of a dominant papillary subtype. 
In summary, BRAF mutations are more commonly seen in PTCs with a dominantly 
papillary morphology, and are more common in PTCs diagnosed in adulthood rather 
than childhood. The low frequency of BRAF mutation in PTCs from children exposed or 
not exposed to radiation suggests that, as with RET oncogene rearrangements, the age 
of the patient at diagnosis is a significant factor. It is therefore important to ensure that 
cases are appropriately age matched when seeking to identify radiation related changes 
in molecular biology of tumors. One study has also shown that in post-Chernobyl PTCs 
from Belarus, BRAF can be activated by gene rearrangement. In this case, the C-terminal 
region of the BRAF gene is fused to the first eight exons of the AKAP9 gene building 
the AKAP9/BRAF fusion gene [4]. However, as is the case with the early studies of RET 
rearrangement in post Chernobyl PTCs, this study lacked age matched controls and it is 
therefore unclear whether this finding is related to radiation or to the age of the patient 
at operation.
Other proto-oncogenes
Although RET/PTC and BRAF alterations are the commonest oncogene alterations 
seen in PTC, rearrangements and mutations of other genes are also observed, but at 
a much lower frequency. NTRK1 encodes the high affinity nerve growth factor (NGF) 
receptor, and is occasionally rearranged in PTC. NTRK1 fusion partners are the genes 
TMP3, TPR and TFG [41,42].  The NTRK1 rearrangement, is only present in about 11% of 
sporadic PTCs [43], and is rare (3.3%) in post-Chernobyl thyroid tumors [44-46]. 
Other types of thyroid cancer are known to involve much different oncogenes, such 
as the RAS oncogene [47] in follicular carcinoma or TP53 in anaplastic carcinoma [48]. 
Mutations of the thyroid stimulating hormone receptor (TSHR) gene occur in follicular 
carcinoma and benign thyroid tumors [49,50]. Santoro et al. [21] examined whether one 
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of these molecular changes had an influence on the development of PTC after exposure 
to radiation. The group studied 128 PTC of post-Chernobyl patients who received 
surgery before the age of 15, all of whom were from Ukraine. In addition to RET 
rearrangement, reviewed in the section above, mutations in the RAS, TP53 genes, and 
exon 10 of the TSHR were also analysed and correlated with the morphological status of 
the tumor samples. 
Alterations in the other genes of interest were not found to be present in the post-
Chernobyl PTC cohort. Other studies could also not demonstrate correlation of TSHR 
or TP53 mutations in thyroid carcinogenesis after radiation exposure [51-54]. RAS 
mutations are not commonly found in sporadic PTCs, although they are identified in 
follicular thyroid tumors, and detection in radiation-induced childhood PTC is similarly 
rare [39,53,55]. 
These results show that mutations in the TP53 and H-, N-, and K-RAS genes play no 
important role in the carcinogenesis of radiation-induced PTC.
Studies on genomic profiling 
Array-based comparative genomic hybridisation (aCGH) is a technique that allows an 
objective and quantitative examination of copy number changes of the entire genome at 
a high resolution. BAC clones covering the whole genome in 1MB distances are spotted on 
glass slides and used for hybridisation with probe sequences of a tumor sample. Genomic 
alterations such as deletions or amplifications are detected with a greater sensitivity and 
improved resolution (1MB) than by karyotyping, but chromosomal rearrangements such as 
translocations and inversions cannot be identified using this technique. aCGH is also capable 
of detecting copy number variations which occur regularly in normal tissue and need to be 
distinguished from their pathogenic counterparts. 
Unger et al. [56] analysed 33 patients who developed PTC following the Chernobyl 
accident for chromosomal aberrations using aCGH and validated the results by FISH. The 
cohort was a mix of 13 children and 20 adults with known RET/PTC rearrangement status. 
RET/PTC positive cases and RET/PTC negative cases were compared, as well as children 
versus adults. In all cases, deletions occurred with a higher frequency than amplifications. 
This might have been predicted, as radiation is thought to introduce chromosomal breaks 
which may lead to deletions, translocations or inversions rather than a chromosomal gain. 
Losses were predominantly on chromosomes 1, 6, 7, 9, 10, 11, 12, 13, 16, 19, 20, 22 and gains 
on chromosomes 10, 12, 19, 20, 21. Hierarchical clustering distinguished the three groups; 
childhood RET/PTC positive, adult RET/PTC positive and adult RET/PTC negative. RET/PTC 
positive cases differed significantly for a region on chromosome 1p which was deleted in 
adults, but not in children. All RET/PTC positive cases differed significantly from the negative 
cases in losses on 1p, 7p, 9, 13q and gains on 3q, 4p, 12q, 21q. Deletions of regions on 
9q, 10p, 10q and 22q had also been observed in other studies on thyroid tumors [57-61]. 
Hence, these aberrations seem to be more specific for carcinogenesis in thyroid than for the 
exposure to radiation and hence cannot be considered as radiation specific biomarkers. Gene 
detection in the altered regions revealed 31 candidate genes which are known to be involved 
in tumor progression and 21 tumor suppressor genes which specifically map to deleted 
chromosomal regions. It is of note that the majority of these genes is known to be involved 
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in thyroid carcinogenesis, and a further study giving a comparison with sporadic PTCs would 
be necessary to define a specific role in radiation induced tumor development. The genes 
identified are involved in the molecular pathways of apoptosis, interleukin-27, angiopoietin 
receptor and the PI3K/MAP kinase. The data reflects a large heterogeneity in post-Chernobyl 
PTC which suggests the existence of various routes of tumor development. In terms of 
biomarker screening this may imply that a whole panel of markers will be necessary for an 
exact detection of a radiation signature.
Stein et al. [62] used tumor and matching normal tissue of 10 Ukrainian patients with 
post Chernobyl PTC to examine copy number changes and gene expression. The latency for 
these tumor patients was 13-14 years, and age at exposure varied from 3 months to 18 years 
whereas age at operation was from 14-31 years.
In studies on sporadic PTCs, copy number alterations (CNAs) are detected with a low 
frequency. Depending on the study, the occurrence of gains and losses ranges between 
2-50% [7,59,63]. Detection is strongly dependent on the method used and the conventional 
CGH and cytogenetic approaches used in these studies have not the same high resolution as 
the currently used array-based CGH (aCGH). Stein et al. used high resolution SNP array CGH 
technology for CNA examination. Several amplifications on chromosome 22 were detected 
in all 10 samples. Also, chromosomes 1 and 12q show amplifications with high frequency. 
Further, less frequent amplifications on 5p, 9q, 16p, and 21q were also detected. Deletions 
were identified in chromosomes 21q and 14q, and several deletions on 1q, 6p, 9p, 10p, 13q, 
and 22 were restricted to 2 tumors specifically. In general, deletions were less common in 
PTC than amplifications independently from radiation exposure or sporadic occurrence. 
Although radiation is thought to generate an increased amount of deletions, translocations 
and inversions due to chromosomal damage, there is no direct evidence that the number of 
chromosomal aberrations in radiation-induced PTC is higher than in sporadic PTC. However, 
some aberrations seem to occur preferably after radiation exposure. Chromosome 22 was 
reported in several studies to be affected in post Chernobyl patients [59,64,65] and was 
associated with tumor aggressiveness in younger patients. Gene expression of genes in these 
regions was determined and compared with gene expression in sporadic tumors. 41 genes 
were specifically upregulated in post Chernobyl pediatric PTC but not in sporadic PTC, and 
the ones with the strongest overexpression were TESC, PDZRN4, TRAA/TRDA, GABBR2, CA12, 
MPZL2, SCG5, PDZK1IPI, AMIG02, NOVA2, and TNIK. The genes with the largest downregulation 
of expression from a total of 24 genes were PAPSS2, PDLIM3, BEXI, ANK2, SORBS2, PPARGCIA, 
MT1M, CTGRF, LYVE1, and OGDHL. Only one gene on chromosome 22, FBLN1, was reported to 
be specifically downregulated. It would be of interest to examine these genes further for their 
potential usefulness as biomarkers of radiation exposure.
Another study on chromosomal aberrations was carried out by Hieber et al. [34]. A cohort 
of 23 patients from the Ukraine who developed PTC after the Chernobyl accident were 
examined for chromosomal aberrations and RET/PTC rearrangements. The median age of 
the patients at operation was 21 years old. SKY (spectral karyotyping) was performed and 
revealed chromosomal aberrations in 14 of the cases, most frequent on chromosomes 7, 10, 
11, 21, and 22. It is unknown whether these aberrations are related to radiation exposure as 
no group of sporadic PTC was included in this study [6,13,14]. As discussed earlier, studies 
on sporadic thyroid cancer had already described aberrations of chromosome 22 as a 
cytogenetic event in subtypes of PTC.
152
Chapter 7
None of the above mentioned studies was able to define a biomarker specifically 
targeted to radiation exposure. This may be partially due to the design of the studies as 
confounders such as age at operation, ethnic origin and histology of the tumor play a role in 
the molecular phenotype of tumors, and the cohorts studied often lack matched controls.
Hess et al. [66] designed a study to specifically address the question whether there 
are genomic alterations that correlate with exposure to radiation. A cohort of 56 patients 
with PTC was matched by age at operation and residency. The patients were known to 
be exposed to radiation (33 patients born before April 1986) or not exposed to radiation 
(19 patients born after January 1987). A second cohort of 28 PTCs (16 exposed and 12 
unexposed) matched on the same criteria was selected to validate the results. aCGH 
and FISH were performed as reported in a previous study [56] to evaluate chromosomal 
aberrations that differed between exposed and unexposed cases. Amplifications were 
found to be more frequent than deletions which are in agreement with the findings of Stein 
et al. [62]. In general, DNA gains (n=81) were more frequent than DNA losses (n=63). Five 
regions on chromosomes 1, 3, 4, and 12 were lost, and six regions on chromosomes 12, 19, 
20, and 22 were gained in all cases investigated. Hierarchical cluster analysis separated the 
array CGH profiles into two main clusters, 1(n=23) and 2 (n=29). Cluster 2 was subdivided 
into two subclusters, 2-1 (n=14) and 2-2 (n=15). Cluster 1 contained significantly more RET/
PTC positive cases compared with cluster 2 (p=0.0096). Large tumors (pT2 and pT3) were 
associated with cluster 1 (p=0.00087). Tumors that had metastases to regional lymph nodes 
(N1) were predominant in cluster 1 and cluster 2-2 (p=0.04). Univariate supervised analysis 
showed associations [false discovery rate (FDR) <0.05] of CNAs with tumor size (gain of 
1q21.1–23.3, 7q22.1, 9p24.3, 10p15.3–15.1, 10q26.13–26.3, 11p11.12-cen, 12q24.11–24.23, 
and 16q22.1–23.3) and sex of patients (loss of 5q23.3–31.3). A DNA gain on chromosome 
7 (7p14.1-q11.23, 32.1Mb in size) was exclusively associated with a subgroup of patients 
exposed to radiation after Chernobyl (univariate supervised analysis; FDR<0.05). The 
alteration was present in 13 out of 33 cases from the exposed group and in none of the cases 
from the unexposed group (p=0.0015, FDR=0.035). This finding was verified by array CGH 
analysis of an independent validation set consisting of 28 PTC cases (16 exposed and 12 
unexposed). FISH analysis of individual cases revealed that up to 24% of tumor cells exhibit 
the amplification of 7q11. As the cohort was matched on the confounding parameters age, 
residency and RET/PTC status, the gain of 7q11 could be described as the first potential 
marker identified for exposure to radiation. Nine genes identified within this region were 
associated with tumor development according to gene ontology analysis. The five genes 
CLDN3, CLDN4, LIMK1, PMS2L2, and RFC2 showed no significant change in expression, 
whereas the three genes PMS2L3, PMS2L11, and STAG3L3 were significantly overexpressed 
in tumors with gain compared to those with normal copy number. CLIP2 was found to be 
overexpressed in exposed tumors in general, independently from the presence of the gain 
of 7q11. CLIP2 (Cap-Gly domain main containing linker protein 2) is a relatively unknown 
gene with putative functions in microtubule formation, chromosome segregation and cell 
division. As these are mechanisms which become perturbed in cancer development, there 
might be a cancer-related function of CLIP2, but its involvement in tumorigenesis, and 
especially radiation-induced tumor development, is currently unknown. 
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Interestingly, the gain on chromosome 7q11 was already reported in a previous study 
of Richter et al. [61], who used conventional CGH to analyse chromosomal aberrations 
in post-Chernobyl PTC. A cohort of 60 children presenting with PTC after the Chernobyl 
accident was used for the study. The 48 female and 12 male patients were matched on age 
at exposure, age at operation and residency. 30% (18 cases) had an altered chromosomal 
profile. The most frequent deletions were observed on chromosomes 16p, 16q, 20q and 
22q, and amplifications of chromosomal regions on chromosomes 4, 7q11.2-21, 13q21-22, 
and 21. The region 7q11.2-21 overlaps with the region described in Hess et al., but none 
of the other CNAs identified in this study correspond with those found by Hess et al. The 
other CNAs idenified may be more related to the age of the patients at operation or the 
behavioural characteristics of the tumor. Deletions on chromosome 22 occur in PTC of 
patients of younger age and thyroid carcinoma with an increased invasive and metastatic 
potential [67,68,59]. Imbalances on chromosome 16 were reported earlier to be involved in 
various forms of thyroid cancer [69,57]. 
The results of these studies are summarised in Table 7.1.
Table 7.1
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Genetic association studies using germline DNA variants
Genetic association studies are aimed at the exploration of the link between genotype 
and phenotype to  facilitate the determination of genetic risk factors for the potential 
development of disease. These studies evaluate gene polymorphism, usually the single 
nucleotide polymorphism (SNP) in retrospective or prospective case-control studies. 
In general, there are two methodological approaches to selecting which and/or how 
many SNPs need to be analyzed. The first one, the so-called candidate gene approach, 
hypothesizes that genetic variations in one or in a limited number of genes may influence 
the risk for or the phenotype of a given disease. A more comprehensive way is hypothesis-
free; it employs analysis of the whole genome, hence the genome-wide association study 
(GWAS). To date, a number of investigations have been done in the area of thyroid cancer, 
mostly in sporadic cases, with a few of those exploring the radiation-induced thyroid cases.
Candidate gene approach
In a study investigating loss of heterozygosity (LOH) for three different SNPs of the RET 
gene (G691S, L769L, and S904S), no evidence of such was observed in 28 of 46 radiation-
related papillary thyroid carcinomas (PTC) from Ukraine and Belarus that were heterozygous 
for at least one of the three SNPs under analysis [70]. A microarray investigation performed 
later and independently was consistent with these findings [71]. In the additional 68 cases, 
the rare S allele of G691S was significantly more frequent in patients older than 30 years old 
as compared to the younger subjects. Since excess radiation risk for PTC in the individuals 
exposed after they are 20 years old is low and it further declines with age at exposure, the 
study concluded that RET polymorphisms may rather influence sporadic but not radiation-
induced thyroid carcinogenesis.
A study of the Arg72Pro polymorphism of the TP53 gene (which encodes a tumor 
suppressor protein TP53 commonly reffered to as p53) in 48 pediatric/adolescent and 68 
adult patients with PTC exposed to Chernobyl radiation from Ukraine and Russia, and 53 
adult patients with sporadic PTC and 313 healthy controls from Russia found that the Arg/
Arg homozygotes were significantly less frequent in adult patients than in children and 
adolescents [72]. No LOH or imbalanced TP53 allele expression was observed in tumor 
tissues of heterozygous individuals. It was proposed that TP53 genotype other than Arg/
Arg may contribute to the risk of development of PTC in individuals exposed to radiation 
during their late childhood, adolescence or in young adulthood, particularly in females 
aged between 18 and 30. Interestingly enough, an elevated risk for thyroid cancer was 
reported in females exposed to Chernobyl fallout at the age below 30 years in a radiation 
epidemiological investigation [73].
A subsequent study extended to the analysis of 9 SNPs in 5 genes involved in DNA 
damage response (ATM, XRCC1, TP53, XRCC3 and MTF1) performed in 255 PTC patients 
(123 from Chernobyl areas and 132 sporadic) and 596 healthy controls (198 residents of 
Chernobyl areas and 398 subjects without history of radiation exposure) demonstrated that 
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the ATM G5557A and XRCC1 Arg399Gln polymorphisms, regardless of radiation exposure, 
were associated with a decreased risk of thyroid cancer [74]. Of note, the ATM IVS22-77 T>C 
and TP53 Arg72Pro SNPs interacted with radiation exposure: the ATM IVS22-77 associated 
with the increased risk of sporadic PTC whereas TP53 Arg72Pro correlated with the higher 
risk of radiation-induced PTC in adult patients, in support to the study which involved the 
Ukrainian patients described above [72]. An issue of gene-gene and gene-environment 
interactions was addressed in the analysis of ATM/TP53 genotypes. Some of those strongly 
associated with either sporadic or radiation-induced cancer suggesting that polymorphism 
of these genes may modify the risk for PTC of different etiology.
Genome-wide association studies
The genome-wide association studies (GWAS), sometimes also referred to as molecular 
epidemiology investigations, are conducted using advanced technologies to rapidly and 
cost-effectively analyze genetic differences between individuals with specific diseases 
compared to healthy individuals. Usually, the studies are performed in two or more 
stages. First, genotyping of a large number of SNPs in a relatively limited sample set, 
which is called the training set, is performed on microarrays. The purpose of this step 
is to tentatively determine the potential candidate polymorphisms at liberal p value. 
Subsequently, genotyping of full or narrower set of SNPs in, again, a relatively small sample 
set is undertaken to achieve more stringent p value. Further on, a validation study is 
performed by genotyping a narrow set of pre-determined SNPs in an extended sample 
set to increase p value stringency or to disprove the association. This last step is commonly 
performed in the single-track assays such as e.g. TaqMan. Finally, a strict statistical meta-
analysis is done, which combines the results obtained at different stages, with correction 
for multiple testing. Eventually, one or several SNPs might be determined as conferring the 
association with the risk for disease. A functional study might be further undertaken to 
clarify the mechanism by which this SNP or a gene with which this SNP is in strong linkage 
disequilibrium (LD) might be involved in the pathogenesis of a given disorder.
Before discussing the results obtained in Chernobyl PTCs, it is necessary to mention 
several appropriately powered studies of genetic predisposition to sporadic thyroid cancer 
published recently. The first one, employing a sample set of 962 cases of differentiated 
thyroid cancer (i.e., mostly PTC and limited number of FTC combined) and 38,923 
controls, reported rs965513, a SNP located at chromosome 9q22.33, 59 Kb upstream 
(centromeric) to the FOXE1 gene encoding a thyroid-specific transcription factor TTF2, as 
the strongest genetic marker (OR=1.75; 95% CI 1.59-1.94; p=1.7x10-27) associating with 
thyroid malignancy in individuals of Iceland, Spain and the USA of European descent [75]. 
This study also claimed another SNP, rs944289, on chromosome 14q13.3 in the area of 
the NKX2-1 gene that encodes the TTF1 transcription factor, to be a marker for thyroid 
cancer (OR=1.37; 95% CI 1.24-1.52; p=2.0x10-9). A consequent study of the same group, 
based on a sample set of up to 1,150 cases and 41,448 controls, found 3 additional SNP 
associating with low TSH levels in population also to be the markers of risk for thyroid 
cancer. These are rs966423 on 2q35 (OR=1.34; 95% CI 1.22-1.47; p=1.3x10-9), rs2439302 
on 8p12 (OR=1.36; 95% CI 1.23-1.50; p=2.0x10-9) and rs116909374 on 14q13.3 (OR=2.09; 
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95% CI 1.68-2.60; p=4.6x10-11) [76]. With regard to genetic markers in the FOXE1 proximity, 
it is important to take into account the results of an independent study of 768 tag-SNPs 
in 97 genes which were initially genotyped in 615 PTC cases and 525 controls from Spain 
and then in 482 patients with PTC and 532 controls from Italy for validation [77]. The target 
genes were selected based on their differential expression in primary thyroid tumors or 
the involvement in thyrocyte biology, metabolism and/or carcinogenesis such as the MAP 
kinase, JAK/STAT and TGF-beta pathways. An SNP, rs1867277, within the LD block spanning 
FOXE1 and located at the 5’UTR of the gene was identified to associate with PTC (OR=1.49; 
95% CI 1.30–1.70; p=5.9x10-9). Functional study demonstrated that this SNP affects FOXE1 
expression by differentially recruiting the USF1/USF2 transcription factors. 
At present, the results of only one investigation of Chernobyl PTCs from Belarus 
employing GWAS have been reported [78]. The developments of this project, however, 
required the involvement of additional PTC cases and controls from Ukraine. Therefore, it 
seems pertinent to describe this study here. 
During the first phase of the molecular epidemiology study undertaken in the frame 
of Nagasaki University’s Global COE Program supported by the Ministry of Education, 
Culture, Sports, Science and Technology (MEXT) of Japan for 2007-12, a total of 667 
patients from Belarus diagnosed for PTC in 1989–2009 and 1,275 controls from Belarus 
and Russia were studied, of which 408 cases and 627 controls were genotyped using 
the Illumina microarrays accommodating over 500,000 human SNPs; the rest of samples 
were subjected to the validation study. Statistical meta-analysis has discovered 3 SNPs at 
chromosome 9q22.33 significantly associating with Chernobyl PTC with a p-value order 
of 10-9 (Fig. 7.3). This value indicated a very significant association which surmounted the 
genome-wide threshold of 2x10-7. For one of the detected SNPs, rs965513, which was 
used for validation, a p-value of 4.8x10-12 and an odds ratio of 1.65 (95% CI 1.43–1.91) was 
obtained after meta-analysis. 
Figure 7.3. Manhattan plot of the GWAS results of the first stage of Chernobyl PTC study. The p 
values calculated by the Trend chi-square test for 506,840 autosomal SNPs are plotted in -log10 scale 
with respect to their chromosomal positions. The horizontal line indicates the Bonferroni adjusted p 
value for genome-wide significance.
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In the second phase of the study, the sample set was expanded to include additionally 
286 PTC cases from Belarus and 145 from Ukraine, and 257 controls from Belarus, 157 from 
Ukraine and 620 from Poland. Thus, a total of 1,098 PTCs from Belarus and Ukraine, and 
2,309 controls (both cases and controls that passed the quality control) from the three 
countries were included. The number of samples genotyped using Illumina microarrays 
was 847 PTC cases and 1,240 controls; validation study using single-track TaqMan assays 
included 274 cases and 1,023 controls.
Among all the targets tested, only 3 SNPs displayed significance in the training and 
validation sets while all other did not pass validation. Two SNPs were around or in the FOXE1 
gene locus on chromosome 9q22.33: rs965513 (OR=1.69; 95% CI 1.51–1.90; p=5.8x10-19), 
and rs1867277 (OR=1.52; 95% CI 1.26–1.83; p=1.4x10-5). The third SNP that displayed 
significant association was in the NRG1 locus on chromosome 8p12, rs2439302 (OR=1.35; 
95% CI 1.16–1.57; p=9.1x10-5). Notably, all three SNPs detected in our Chernobyl series had 
effect size, in terms of OR, very similar to those reported in sporadic thyroid cancer studies. 
Based on these observations it was concluded that these SNPs are the markers of PTC of 
either radiation or sporadic etiology. 
It is worth mentioning that besides the 3 SNPs that displayed significant association 
signals, the study also identified 11 potential candidate SNPs in or around 10 genes which 
were significant on microarray analysis with p values ranging 4.7x10-7 – 1.6x10-4. However, 
none of them, when subjected to validation study, passed it displaying the p-values from 
0.07 – 0.944. Therefore, all of them were conservatively judged as having no association 
with Chernobyl PTC even though their significance (a p-value) for association ranged 
6.0x10-6–5.0x10-3 on final meta-analysis. The SNPs in vicinity of NKX2-1, MBIP and DIRC3 
previously reported to be associating with sporadic thyroid cancer were insignificant in the 
study thus pointing on the specific association of these genes with sporadic thyroid cancer.
Figure 7.4. Risk factors for development of papillary thyroid carcinoma after internal exposure 
to radioiodine. Genetic predisposition is added to those previously established to affect the risk: 
exposure dose, younger age at exposure, iodine deficiency, male sex. Note that genetic markers 
associating with risk for Chernobyl PTC are the same found for sporadic PTC, around or in the FOXE1 
(the strongest) and NRG1 gene loci. Several markers appear to be associating with the risk for 
sporadic thyroid cancer only: in or around the DIRC3, NKX2-1 or MBIP genes. 
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As a whole, molecular epidemiology study of Belarussian and Ukrainian PTCs leads to 
an important corollary that among the genetic factors affecting risk for radiation-induced 
thyroid cancer, the strongest markers are the same that confer predisposition to the sporadic 
form of this type of malignancy. Genetic markers of radiation-related and sporadic partly 
overlap yet the absence PTC-associating markers on 14q13.3 (i.e., NKX2-1 or MBIP), and 2q35 
(DIRC3) from the Chernobyl series suggests they are specific to PTC developing without 
radiation history. As shown in Figure 7.4, the results obtained in the study of Chernobyl 
PTC permit the inclusion of genetic predisposition to the list of risk factors for radiation-
induced thyroid carcinogenesis known from the earlier experience. The fact that GWAS 
has not revealed genetic markers specifically associating with radiation-related but not 
sporadic thyroid cancer does not rule out the possibility of their existence. Further studies 
with higher resolution, such as e.g. next-generation sequencing, may shed light on this 
problem and will probably refine our understanding of radiation-induced carcinogenesis 
by addressing issues of gene-gene and gene-environment interactions.
Possible implication of FOXE1 in pathogenesis of PTC
The three genetic studies, two of sporadic thyroid cancers and one of radiation-induced 
Belarussian and Ukrainian PTC, have concordantly identified the FOXE1 (TTF2) locus as a 
marker of inherited susceptibility for PTC of different etiology [75,77,78]. The intronless 
FOXE1 is a member of the forkhead/winged helix family of evolutionarily conserved 
transcription factors [79]. In humans, FOXE1 is a key player in thyroid organogenesis, 
thyrocyte precursors migration and differentiation with onset of expression in the 
thyroid primordium at Carnegie stage 15 [80,81]. FOXE1 is a transcription activator of 
thyroperoxidase (TPO) and thyroglobulin (TG) genes [82,83]. 
FOXE1 involvement in thyroid diseases remains scarcely addressed. Using RT-PCR or in 
situ hybridization, Sequeira et al. found FOXE1 (TTF-2) expression in about 60% of human 
thyroids [84]. In benign thyroid lesions FOXE1 expression was observed in 43–100% cases. 
In thyroid malignancies, FOXE1 was expressed in 44% follicular carcinomas, 65% PTC and 0 
(of 2) anaplastic carcinomas. Nonaka et al. reported strong diffuse immunohistochemical 
TTF-2 staining in 50 – 100% tumor cells in PTC, follicular adenoma, follicular carcinoma and 
poorly differentiated thyroid carcinoma [85]. Medullary thyroid carcinomas were weakly 
positive in 75% cases and anaplastic thyroid carcinomas were virtually all negative. In a 
study by Zhang et al., nuclear expression of TTF-2 was found to be gradually decreasing from 
follicular adenoma to anaplastic carcinoma in accordance with tumor dedifferentiation 
[86]. Abnormal TTF-2 expression in the cytoplasm displayed the opposite trend except for 
anaplastic carcinoma in which TTF-2 expression was generally low. Despite genetic studies 
strongly suggest FOXE1 implication in PTC, and there is an alteration of FOXE1 expression 
and localization in cancer cells, its role in tumor development remains unknown.
To clarify the role of FOXE1 in PTC, the patterns of FOXE1 immunohistochemical expression 
 in 42 tumors and adjacent normal thyroid were analyzed, and then their relationship with 
morphological characteristics of the tumor and patients’ genotypes was investigated [87].
FOXE1 exhibited nuclear and cytoplasmic staining in normal thyroid follicular cells. 
Nuclear immunoreactivity was strong or moderate, while cytoplasm showed weak-intensity 
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staining. Approximately one-third of all nuclei were not stained, whereas no cytoplasmic 
expression was noticed in about 25% of cells. More uniform pattern of FOXE1 expression 
was observed in thyroid cells at the vicinity of PTC border within 100-300 μm tissue layer 
in which most cells showed strong nuclear and moderate cytoplasmic immunoreactivity.
FOXE1 expression in cancer tissue displayed approximately the same extent as in the 
normal counterpart. Cells at the tumor border and those in close proximity to the border 
showed the highest intensity of cytoplasmic and nuclear expression. Neoplastic cells in the 
tumor center exhibited substantially lower intensity scores and an obvious loss of nuclear 
expression.
A significant increase of total FOXE1 score in cancer tissue compared to normal thyroid 
(p<0.001) which was contributed mainly by the cytoplasmic expression was found while the 
nuclear expression remained higher in non-neoplastic thyroid cells (p<0.001 and p<0.05, 
respectively). Thus, cytoplasmic FOXE1 expression was an essential feature of cancer cells 
whereas prominent nuclear expression was characteristic for normal cells.
Statistical analysis confirmed preliminary observations of the gradient FOXE1 expression 
from central to peripheral areas of tumor and normal counterparts. Both cancer and 
surrounding normal thyroid tissue demonstrated the strongest FOXE1 expression in the 
areas immediately adjacent to the tumor border comparing with the staining scores of 
distant regions (p<0.001). Of note, the highest nuclear scores were on the normal tissue 
side and the highest cytoplasmic scores on the cancer side. There were notable changes in 
FOXE1 immunoreactivity with distance from the tumor border, such as increasing number 
of negative nuclei in normal thyroid tissue and increasing number of negative nuclei along 
with decreasing cytoplasmic intensity in cancer tissue (Fig. 7.5).
Figure 7.5. Four distinct patterns of immunohistochemical FOXE1 expression in different zones 
of normal thyroid (A and B) and tumor tissue (C and D), original magnification ×200. (A) In the normal 
thyroid tissue at the distance >300 μm from the tumor border there is a considerable variation of 
nuclear and cytoplasmic FOXE1 expression with 25 – 35% FOXE1 negative cells. (B) In the normal 
thyroid tissue immediately (≤300 μm) adjacent to invasive or encapsulated tumor border) most 
cells are FOXE1 positive with the highest nuclear and moderate cytoplasmic intensity. (C) In the 
tumor tissue at the invasive front or subcapsular region (<300 μm) regardless tumor border contacts 
adjacent thyroid parenchyma or extrathyroid tissues, virtually all cells demonstrate the strongest 
cytoplasmic and moderate nuclear FOXE1 expression. (D) Tumor tissue at the distance >300 μm 
from the tumor border shows mainly monomorphic low to moderate cytoplasmic expression with 
negative or weak nuclear staining.
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On multivariate logistic regression analysis it was demonstrated that among all 
demographic and pathological variables entered in the model, only two, namely tumor 
multifocality (p=0.032) and rs1867277 polymorphism in the FOXE1 5’ UTR (p=0.037), 
significantly associated with nuclear FOXE1 expression in the zone of tumor cells confined 
within the 300 μm to the tumor border; capsular invasion displayed marginal significance 
(p=0.051). Both multifocality and variant genotype other than homozygous for the major 
allele (the dominant model of inheritance) associated with the higher FOXE1 expression. 
Thus, FOXE1 displays an aberrant cytoplasmic expression in PTC suggestive of a possibility 
of a role other than transcription factor or of the existence of other factors causing translocation; 
perhaps such translocation may contribute to cancer cell biology. FOXE1 overexpression in 
the cytoplasm in tumor cells may also reflect activation of FOXE1 regulating pathways (Shh/
Gli and Wnt) which are switched on during thyroid carcinogenesis [88]. The precise role of 
cytoplasmic FOXE1 requires functional studies to determine whether it is an active process 
involved in carcinogenesis or it is a consequence of malignant transformation.
The interface between normal and cancer tissues is a battlefield of invading cancer cells 
and the host. Many biological processes in cancer show highest intensity at the border, e.g. 
cell metabolism changes, proliferation, neovascularization, and invasion. The significant 
difference of FOXE1 expression between the periphery and the center of PTC is in line with 
these notions of particular processes at the tumor border. The gradient in non-neoplastic 
thyroid tissue adjacent to PTC was also found. Such kind of distribution is not described 
well for normal counterpart. Observations of the sharp reduction of FOXE1-positive cells 




The previous sections have concentrated on the molecular aberrations identified in the 
genome. Although many of these will result in changes at the RNA level, other factors can 
affect RNA expression. The next section therefore summarises data from transcriptomic 
studies using RNA expression techniques. 
The power of the microarray technology in contrast to conventional analysis is in enabling 
an observation of the genome-wide gene expression profile for a given population within a 
single experiment. Gene-specific oligonucleotide sequences are spotted on glass slides and 
used for hybridisation of a preprocessed RNA sample. Technical issues such as non-specific 
binding of the fluorophore or hybridisation artefacts can influence the evaluation and need 
to be controlled for. The large amount of data created may be difficult to analyse and needs 
implementation of explorative statistical tools for normalisation and correction, as well as 
for detection of significant hits. Gene expression microarray studies are carried out to define 
diagnostic and prognostic markers and signatures. In Ukrainian post-Chernobyl PTCs, several 
studies were specifically designed to address the question whether there is a molecular 
signature for radiation-induced thyroid cancer. Table 7.2 gives an overview of the outcome. 
No significant findings were reported concerning the transcriptome of exposed and non 
exposed tumor tissue, but various studies identified subsets of genes involved in thyroid 
carcinogenesis and their related signalling pathway regulations.
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Table 7.2 
Overview of conducted gene expression studies in the Ukrainian cohort
Author
[ref.]












relation to 131I 
dose
Cell cycle & growth and 
differentiation, Cell adhesion, 
Microenvironment/metabolic 
changes, Transcription factor 
and DNA modification through 
methylation ; w/o significant 
enrichment of a certain 
pathway
AJAP1, FAM38A, CA12, 
LMO3, ZNF493, 
MTA1, SLC19A1, CDK12, 














44.5% of genes 
on the array
Immune response, Cytokine 
activity, Chemokine activity, 
Thyroid hormone generation, 
EGFR signaling pathway, 
Activation of JNK activity , MAP 
kinase phosphatase activity, 
Extracellular matrix, Peptidase 
activity, Protease inhibitor 
activity, Laminin complex, 
Collagen, Cell–cell adhesion, 
Integrin complex; p-values 
below 0.05
ANXA1, CDH3, CLDN1, 
DUSP5, GPX1, HMGA2, 
NELL2, NRCAM, SLIT1, 
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n/a two subsets of 256 and 118 
genes separate radiation-
induced from sporadic; 
homologous recombination XRCC2, SHFM1, RAD51C, 
MUS81, RAD51L1, RAD51, 
RAD50, RAD54B, RAD54L, 










from normal not 
exposed tissue
Chronic myeloid leukaemia, 
Neutrophin signalling pathway, 
MAPK signalling pathway,  
Insulin signalling pathway, 
Renal cell carcinoma, Pancreatic 
cancer, Regulation of actin 
cytoskeleton, Spliceosome, 
mTOR signalling pathway, 








childhood PTC in 
comparison to the 
matching normal 
tissue
n/a Cancer, Cellular Growth and 
Proliferation,  Reproductive 
System Disease, Cellular 
Movement, Cell-to-Cell 
Signaling, and Cell-Mediated 
Immune Response
LRP4, IGSF1, ODZ1, CITED1, 
SLIT1,HMGA2, SERPINA1, 
KCNJ2, AGR2, TACSTD2, 
NELL2, CHI3L1, TPO, TFF3, 
CRABP1, COL9A3, MATN2, 




Detours et al. [89] performed Micromax Microarray experiments to evaluate the gene 
expression profile of twelve post-Chernobyl PTCs. In addition, eight sporadic PTCs and 
thirteen autonomous adenomas from Belgium, France and the US were arrayed. The 
group was interested whether the gene expression pattern of the radiation exposed 
cases would reveal a radiation-related signature and applied several unsupervised 
and supervised analyses to the obtained microarray data. Unsupervised hierarchical 
clustering was able to distinguish between PTCs and adenomas, but could not separate 
the sporadic from the post-Chernobyl PTCs. Similarly, RET/PTC rearrangement was not 
a criterion which could separate the PTCs into two groups. Significance analysis of 
microarray (SAM) found 168 genes to be differentially expressed between adenomas and 
PTC with a false discovery rate (FDR) of 1%. Amongst these, a signature of six genes was 
capable of accurately differentiating between adenoma and PTC. No such genes were 
found when analysing sporadic PTC versus post-chernobyl PTC. Instead, a significant 
correlation of the two groups was found which could not be seen for the adenomas. This 
correlation was independent from the methods used and was validated in silico using 
PTC data from Affymetrix microarrays. Patients were not matched on age, residency, or 
sex within this study. Surprisingly, despite the high variation in the clinical parameters of 
the patients, the data correlated significantly and indicated a similarity between sporadic 
and post-Chernobyl cases. The data suggested that no molecular expression signature 
for radiation-induced thyroid cancerogenesis exists. 
Two years later the same group [90] repeated the analysis on Agilent microarrays, which 
support a broader range of genes. The Ukrainian cohort of twelve patients exposed to 
radiation was compared to a French cohort of 14 patients without known radiation history. 
The distribution of histological subtypes was the same in the two groups. Frequencies of 
RET/PTC rearrangement and BRAF mutation were also comparable. Screening for global 
expression profiles revealed no difference between the French and the post-Chernobyl 
PTCs. However, application of a supervised classification algorithm identified a subset 
of genes which was capable of distinguishing French and post-Chernobyl tumors with 
an error rate of 12%. In further experiments in vitro the same authors showed that 200 
mM H2O2 (peroxide) or 2.5 Gy γ-radiation cause a similar transcriptional response in a B 
lymphocyte cell line with a subset of 293 genes having a fold change greater than 1.5. 118 
out of these genes were also able to separate the French and the post-Chernobyl cohort 
with an error of 15%. This implies that peroxide had a major influence in carcinogenesis 
in the French cohort. H2O2 is a byproduct of thyroid hormone synthesis and known for its 
high DNA damaging potential due to its oxidizing properties. H2O2 is considered as a highly 
reactive oxygen species, and free radicals were shown to cause cancers in the thyroid of 
Tg-a1BAR mice [91]. Similarly, ionizing radiation is creating reactive oxygen through the 
radiolysis of water, which is highly abundant in the cellular environment. The etiological 
agents peroxide and radiation both create reactive oxygen species as a cancer initiating 
event which supports the finding of similar global gene expression profiles. An additional 
signature of thirteen genes involved in homologous recombination was able to distinguish 
the two cohorts with an error rate of 15%. The authors matched the groups on clinical 
parameters such as morphology and known molecular aberrations. However, they did not 
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match on age and residency, two independent confounders known to affect data analysis. 
It would also have been interesting to see whether the magnitude of RET/PTC or BRAF 
expression had an influence on the gene expression profile as described in literature [92], 
but such data was not provided.
A more recent study again tried to address the question whether a radiation-specific 
signature is detectable in post-Chernobyl thyroid cancer. Dom et al. [93] chose a carefully 
selected cohort. 22 patients who were exposed to radiation and born before April 1986 
were matched on age and residency in Ukraine to 23 patients born after March 1987 and 
hence not exposed to radiation. The cases were subjected to Affymetrix microarrays and 
expression of single genes was validated using qRT-PCR.
The authors searched for global gene expression variations using hierarchical clustering 
and principal components analysis which successfully separated tumor from normal thyroid. 
However, similar analyses were not able to reveal any differences between exposed and 
non exposed cases. A subset of eight genes was selected according to known involvement 
of their products in carcinogenesis: carbonic anhydrase 12, BH3-interacting domain death 
agonist, clusterin, cyclin D2, trefoil factor 3, low-density lipoprotein receptor-related 
protein 1B, dual specificity phosphatase 1 (DUSP1) and thrombospondin, type I, domain-
containing 7A, and validated by qRT-PCR. All of them were found to be differentially 
regulated in tumor versus normal thyroid tissue. 
Supervised analysis of the data could not distinguish exposed from non exposed 
tumors either, but the normal tissue seemed to have differential gene expression in both 
groups. 
Potential confounding factors such as the clinical parameters sex, age at operation, 
patients’ place of residence (region/oblast) at the time point of the Chernobyl accident, 
morphological subtype of PTC, TNM classification, presence of BRAF mutations or RET/
PTC rearrangements, tumor size and methodological parameters such as batch effects of 
microarray hybridisation or RNA storage time were analysed. The age at operation and 
the time of storage of frozen tissue prior to RNA extraction were found to be associated 
with the radiation exposure, and data was adjusted accordingly. The corrected data was 
evaluated using SAM and a signature of 403 genes was found to distinguish exposed from 
non exposed normal thyroid tissue. All of them were upregulated in the exposed normal 
tissue. The results were validated in silico using an external data set. Gene ontology and 
KEGG analysis of the gene signature in DAVID found pathways with an impact on cancer 
development and proliferation, mainly MAPK, insulin and mTOR signalling pathways, and 
enrichment of cell adhesion-related genes.
Thus, the study was not able to show any differences between exposed and non 
exposed tumors, but the matching contralateral normal tissue in these patients reveals 
significant differences. This could be related to the character of the tumor which is known 
to evolve into diverse subpopulations, whereas the surrounding normal tissue does not 
evolve but may keep a tumor-initiating expression profile. However, such hypotheses 
remain speculative and require validation in an independent set of cases. The signature 
identified could be used to classify a PTC cohort in the two categories - exposed and non 




Although scientists could not detect a clear radiation-related signature in post-
Chernobyl childhood PTC, with the methods used, the collected data highlighted certain 
signalling pathways in exposed over unexposed tumor tissue. The point mutations and 
gene rearrangements observed in PTC stress out a major role for the MAPK pathway in 
thyroid tumorigenesis. BRAF mutations and RET as well as NTRK rearrangements lead to 
constitutive activation of these genes and are supposed to interfere with their downstream 
partners perturbing the pathway cascade. Expression status of other genes - especially in 
post-Chernobyl PTC - was rarely explored. The study of Delys et al. [94] aimed to identify 
certain signalling pathways and their regulation in relation to the physiopathology of 
the disease. 12 PTCs from Ukrainian patients which were exposed to radiation and 15 
sporadic PTCs from French patients plus matching normal tissues were arrayed on Agilent 
cDNA microarrays. The statistical algorithm Significance Analysis of Microarray (SAM) was 
applied, and it was possible to significantly distinguish a characteristic gene expression 
profile for PTC from normal thyroid tissue. The differences in gene expression may relate 
to the observed differences in morphology between tumor and normal tissue. To identify 
individual differentially regulated genes, the data was correlated with two independent 
PTC data sets [95,96]. Only genes which show the same regulation in at least two of the 
data sets were selected for further pathway regulation studies. This resulted in a profile 
of 451 up- and 233 downregulated genes. Eleven upregulated genes (ANXA1, CDH3, 
CLDN1, DUSP5, GPX1, HMGA2, NELL2, NRCAM, SLIT1, THBS2, TNC) and four downregulated 
genes (BCL2, EGR1, EGR2, FLRT2) identified in the microarray data sets were validated by 
qRT-PCR. Additionally, 20 genes were already identified in the literature to correlate with 
the phenotype of sporadic thyroid cancer [97]. GO term analysis with DAVID revealed 
a participation of the genes in the gene list in eleven pathways with a p value <0.05. 
Many of the pathways are related to the immune response which may more reflect the 
infiltration of immune cells into the tumor rather than changes in the tumor cell itself. 
Alteration of cytokines and chemokines was observed in this study as well, which is 
consistent with other studies where PTC is known to evoke a chronic inflammation in 
vivo and in vitro [98]. This could have a direct influence on the recruitment of lymphatic 
cells into the tumor tissue. 
Surprisingly, no deregulation of the MAPK pathway could be found, which would be 
expected for PTC because of the BRAF mutations and RET/PTC gene rearrangements which 
lead to a constitutive expression of those genes. On the other hand, EGF signalling, an 
activator of the MAPK pathway, was significantly altered, whereas ERK specific inhibitors 
of the DUSP family were highly overexpressed as well. c-jun N-terminal kinase (JNK) and 
p38 pathway was another gene cascade significantly altered. Its involvement in thyroid 
carcinogenesis was already suggested previously by immunohistochemical detection in 
tumor but not normal thyroid tissue [99]. Also, overexpression of proteases and protease 
inhibitors which are known for remodelling of the ECM was highly abundant in PTC versus 
normal tissue. This is a well known cancer initiating event and documented to have a 
participation in thyroid cancer [100,101]. 
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Cell migration is another mechanism playing an important role in carcinogenesis. Its 
consequences for tumor development can be observed and are described histopathologically 
[102]. Delys et al. [94] identified several genes from the integrin, cadherin and claudin family 
being deregulated in the tumor tissue, which could have a direct influence on the invasive 
behaviour of the tumor. It would be interesting to apply a principal component analysis to 
these 26 cases of the study to see whether clinical parameters match with these findings, 
and tumors with a higher invasive behaviour consistently show a stronger upregulation of 
these pathways. 
The study could identify a clear difference between PTC and normal tissue and found 
many pathways which are known to be involved in tumor development being differentially 
regulated. The study could not distinguish between radiation-induced and sporadic 
tumors, suggesting that the etiologic agent may be responsible for tumor initiation but 
has no influence on tumor progression. 
Transcriptomic profiles and radiation dose
Previous studies showed that, especially in gene expression analysis, the use of differing 
methods and statistical evaluation algorithms, the sample size and/or selection of control 
populations lead to inconsistent findings between studies. These factors may have 
contributed to the conclusion that neither a radiation-specific signature nor a gene regulation 
mechanism is present in the Ukrainian post-Chernobyl PTC cases. Despite this, a more recent 
study performed by Abend et al. [103] aimed to address the question whether a dose-related 
response to 131I is present and detectable. The patients included in this study were enrolled in 
the Ukraine-American Cohort Study. The patients were all below 18 years old at the time of 
accident and individual 131I measurements were taken within two months after the accident 
[104]. 63 tumor/normal pairs were split in a screening set with 32 cases for Agilent oligo 
microarray gene expression analysis and a validation set with 31 cases for qRT-PCR validation 
of altered genes. Arraying found 2500 genes that were significantly differentially expressed 
between the tumor and the normal tissue, but none of the p values survived multiple testing 
using false discovery rate (FDR). 75 genes were selected based on analysis of a dose-dependent 
differential expression, and this list includes also genes with evidence from previous studies. 
qRT-PCR found 11 of those genes were differentially expressed in tumor but not in normal 
tissue in relation to the dose received. Nine of the eleven genes are involved in the pathways 
cell adhesion (AJAP1, FAM38A), energy metabolism (CA12), transcription or DNA methylation 
(LMO3, ZNF493, MTA1, SLC19A1), and growth/differentiation (CDK12, ACVR2A). These pathways 
are known for their participation in the cellular response to ionizing radiation [105, 106]. The 
importance of five genes (CA12, GALNT7, LMO3, SLC43A3 and FAM38A) was also confirmed by 
others in post-Chernobyl and other radiation-induced childhood thyroid tumors [62, 107]. 
The differential expression of the genes is dose-dependent and linear, however, the three 
genes SLC19A1, SLC43A3 and ZNF493 exhibit some non-linearity. The cellular response to 
radiation is known to be non-linear, and changes over time with an early response to DNA 
damage and a later survival with chromosomal rearrangements [108,109], and the non-
linearity in differential expression may reflect this. Taken together, the eleven genes show 
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a clear difference in expression levels between exposed tumor and exposed normal tissue, 
and further studies on the genomic architecture of these genes will give more insight on 
their ability to serve as biomarkers for radiation exposure. 
In the most recently reported study using material from the patients enrolled in the 
Ukrainian-American cohort, Leeman-Neill et al. [110] hypothesized that chromosomal 
aberrations such as RET/PTC and point mutations have different associations with 131I 
dose. The case series included 26 males (42%) and 36 females (58%) who were resident 
in the areas surrounding Chernobyl, i.e., the Zhytomir (n= 17; 27.4%), Kiev (n=12; 19.4%), 
or Chernigov (n=33; 53.2%) regions (oblasts), and who were between 5 months and 17 
years old (mean 8.0 years) at the time of the Chernobyl accident. The estimated 131I dose for 
patients in the study ranged from 0.008 Gy to 8.6 Gy, with a mean dose of 1.3 Gy. Surgical 
removal of PTCs occurred between October 1998 and December 2007, with time between 
exposure and surgery ranging from 12.5 to 21.6 years (mean: 16.5 years).  
RET/PTC rearrangement was the most common genetic alteration and was found in 22 
(35%) cases, including 14 RET/PTC1 and 8 RET/PTC3 rearrangements. Point mutations in 
the BRAF and RAS genes were found in 9 (15%) and 5 (8%) of the tumors, respectively. All 9 
BRAF mutations were BRAFV600E. Four RAS mutations were detected in NRAS codon 61 and 1 
in HRAS codon 61. No KRAS mutations were found in codons 12 and 13. In addition, these 
tumors were studied for PAX8/PPARγ rearrangement, a prototypic genetic alteration found 
in follicular thyroid carcinoma that occurs with lower prevalence in the follicular variant of 
PTC. Two tumors were positive for PAX8/PPARγ; both were of the follicular variant of PTC. 
In both cases, the fusions were between exon 9 of PAX8 and exon 1 of PPARγ, with several 
expected splice variants of the chimeric PAX8/PPARγ transcripts detected. One tumor had 
more than 1 mutation, harbouring an NRAS point mutation in codon 61 and PAX8/PPARγ 
rearrangement. Twenty five (40%) tumors revealed none of the studied mutations. Patients 
with BRAF or RAS mutations had the lowest dose (0.27 Gy and 0.20 Gy, respectively). 
RET/PTC1 and RET/PTC3 were associated with a higher dose of 1.04 Gy and 1.54 Gy. The 
highest dose of 1.97 Gy had tumors without any of the observed aberrations. There was 
also a significant correlation with the age of the patients, where BRAF and RAS mutations 
associated with older age and RET/PTC rearrangements with younger onset. Hence, it is 
difficult to differentiate between the known effects of age at diagnosis on the molecular 
phenotype of PTC, and the effects of dose, especially in such a small study. The cohort was 
not age matched or subdivided between children and adolescents (aged <19) and young 
adults (aged >19) at surgery. Children have been shown to receive a relatively higher dose 
of radiation due to the smaller size of their thyroid. 
Interestingly, there was a positive correlation of the chromosomal rearrangements with 
residency in the Zhytomir oblast, where the individuals also received a higher radiation 
dose. This oblast is known for a moderate iodine deficiency. As such a deficiency was shown 
to be a risk factor for thyroid cancer in a Belarussian cohort of post-Chernobyl thyroids 
[111], the authors suggest a similar contribution for their findings. 
Further whole genome studies on cohorts matched for the confounders in this study 
(age, sex, region of residence) would be required to convincingly link the findings in this 
paper and that by Abend et al. [103] to dose of radiation.
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In summary, it is now accepted that the initial studies suggesting that post- Chernobyl 
thyroid cancers showed a higher frequency of involvement of the RET/PTC oncogene were 
misinterpreted due to the lack of appropriate age-matched controls. It had been assumed 
that the molecular pathology of thyroid cancer was not influenced by age, but as the 
studies reported above have shown, young onset PTC shows very different pathology and 
morphology when compared with the same disease in adults. Studies using the newer 
“omic” technologies have suggested that there may be subtle differences between PTCs of 
a radiation aetiology compared with age-matched controls, but all of these studies require 
validation in separate cohorts of patients. The studies so far performed on the effect of 
inherited, germline polymorphisms suggest, as with their somatic counterparts, that there 
is little to differentiate radiation associated PTC from sporadic PTC. Attention is now turning 
to studies on potential epigenetic differences (miRNA and DNA methylation), and to next 
generation sequencing technologies to tease out more subtle differences associated with 
a radiation aetiology. Regardless of the final conclusions of these studies regarding the 
relationship between radiation and molecular phenotype, the Ukrainian cases provided 
to the general scientific community through the generosity of Ukrainian patients and the 
staff at the Institute of Endocrinology and Metabolism in Kiev, have been instrumental in 
increasing our knowledge of molecular pathology of thyroid cancer in general, and PTC in 
particular.  It remains to be seen whether any of the data so far generated by these studies, 
and those yet to come, will lead to the development of better prognostic markers for 
thyroid cancer. Unlike many cancers, PTC has a releatively good prognosis, with a predicted 
death rate over 30-50 years of 1%.  Despite this, there is a recurrence rate of 30% [112]. 
Identification of prognostic biomarkers, combined with clinical features would therefore 
aid patient stratification for follow-up. 
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